PubMed Health⌕ Search

Biomedical subjects

J Moro

Publications and source records attributed to J Moro.

6 recordsLinked to original sources
PubMed1992

Treatment of melphalan-resistant multiple myeloma with vincristine, BCNU, doxorubicin, and high-dose dexamethasone (VBAD).

A total of 65 patients (35 male/30 female) with multiple myeloma primarily (33) or secondarily (32) resistant to melphalan and prednisone were treated with vincristine, carmustine (BCNU), doxorubicin, and high-dose dexamethasone (VBAD) at 4-week intervals. Among 60 evaluable patients the overall response was 36.6% (21.6% objective response plus 15% improvements). The response rate was significantly higher in primarily resistant patients than in those becoming resistant after a prior response (48.4 vs. 24.1%, P < 0.05). The median duration of response was 17.5 months. When survival of responders and non-responders were compared by the conventional method, a highly significant difference was observed (P < 0.001). However, using the Mantel and Byar procedure and the landmark method, only a trend for longer survival in the responders was registered. These results indicate that although VBAD is effective in at least one third of patients with advanced multiple myeloma resistant to melphalan, its impact on survival is limited.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1991

Mortality and body weight changes in Aotus nancymai shipped from Iquitos, Peru to Richland, Washington.

Four hundred and fifty wild-caught owl monkeys (Aotus nancymai) were shipped from Iquitos, Peru to Richland, Washington. Mortality and body weight changes from the time of shipment to 30 days after arrival were evaluated using age, sex, and transit time as comparison criteria. No association between mortality and sex, age, or transit time was observed. The mortality percentage from shipment to 30 days after arrival was 2.44%. Both age and transit time had a significant effect on weight changes, but sex did not. Shipping procedures are described.

Age Factors↗
PubMed1986

New congenital deficiency of high molecular weight kininogen and prekallikrein (Fitzgerald trait). Study of response to DDAVP and venous occlusion.

The prolonged partial thromboplastin time observed in the plasma of a 36 year old asymptomatic man was related to the reduced prekallikrein activities (coagulant; antigenic; and amidolytic) and the absence of coagulant and immunologic activities of high molecular weight kininogen (HMWKg). The patient's plasma also exhibited impaired surface-mediated fibrinolysis and impaired generation of kallikrein. The coagulation defect was identified as the "Fitzgerald trait". The levels of CH50, C2, C4 and C-1 inactivator were normal. Venous occlusion in the patient gave rise to a normal release of extrinsic plasminogen activator from the vascular endothelium. The administration of DDAVP led to a FVIII/VWF response which was similar to that obtained in healthy subjects. No alteration could be observed in the contact phase proteins after DDAVP administration.

Adult↗